Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moxifloxacin placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

NCT00964730
View directory record Official record
Conditions
Healthy
Interventions
Talampanel, Moxifloxacin, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2010 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

NCT03958123
View directory record Official record
Conditions
Prolonged QTc Interval, Pharmacokinetic
Interventions
100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

NCT01565720
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Healthy Volunteers
Interventions
Isavuconazole, Placebo, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 7, 2026, 10:40 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

NCT07422298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278, Placebo, Moxifloxacin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

NCT01090661
View directory record Official record
Conditions
Healthy
Interventions
mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough Corrected QT Interval Trial

NCT02073084
View directory record Official record
Conditions
Dyslipidemia
Interventions
K-877 Low Dose, Moxifloxacin, Placebo, K-877 High Dose
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 7, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

NCT01198626
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of Danicopan in Healthy Adults

NCT05016206
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

NCT02807207
View directory record Official record
Conditions
Healthy Subjects
Interventions
A: pacritinib, B: Placebo, C: moxifloxacin
Drug · Other
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

NCT04688632
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions
Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

NCT02165332
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

NCT02027454
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744, GSK1265744 matching placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

NCT05878522
View directory record Official record
Conditions
Healthy
Interventions
sisunatovir, placebo, moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

NCT00798577
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vigamox Ophthalmic Solution, BSS placebo
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2010 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

NCT00708903
View directory record Official record
Conditions
Breast Cancer
Interventions
neratinib, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

NCT01287793
View directory record Official record
Conditions
Healthy
Interventions
tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Cardiac Conduction of GSK1349572

NCT00996021
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

NCT06215521
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 7, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

NCT00360425
View directory record Official record
Conditions
Anemia
Interventions
ferumoxytol, moxifloxacin, placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 7, 2026, 10:40 AM EDT